Why Clovis Oncology Inc Shares Could Bounce Back to $50
Does this analyst make a good case? Or is it just more noise from Wall Street?
ASCO: Cancer Drug Showdown
Ariad, Pharmacyclics, and Johnson & Johnson present impressive data. Clovis battles with AstraZeneca.
The 3 Biggest Biotech Crashes in May
Here's what you need to know about tumbling shares in Insys, Clovis, and Aegerion.
Why Clovis Oncology Inc. Shares Were Clobbered Again
Clovis shares take a beating following ASCO data and analyst commentary. Find out what investors' best course of action is going forward.